Results 21 to 30 of about 110,630 (313)

Study on relationship between genetic abnormalities and clinicopathological features in K hospital's patients with colorectal cancer

Journal of Advanced Biotechnology and Experimental Therapeutics, 2022
The MAPK-ERK, as well as PI3K-AKT signaling transduction pathway, represents a pivotal function in tumorigenesis. Genetic alterations of potential tumor-driven genes, for instance, KRAS, BRAF, NRAS, and PIK3CA can result in uncontrolled cell ...
Linh Dieu Vuong, Ha Hoang Chu, Quang Ngoc Nguyen   +2 more
doaj   +1 more source

BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status [PDF]

, 2006
BACKGROUND: BRAF is a member of RAF family of serine/threonine kinases and mediates cellular responses to growth signals through the RAS-RAF-MAP kinase pathway.
Kazuyuki Kawakami, Andrew Ruszkiewicz, Kawakami, K., Ruszkiewicz, A., Bennet, G., Li, W., Iacopetta, B., James Moore, Wei Qi Li, Barry Iacopetta, Moore, J., Graeme Bennett   +11 more
core   +2 more sources

Traditional serrated adenoma with BRAF mutation is associated with synchronous/metachronous BRAF-mutated serrated lesions [PDF]

, 2017
Aims: To determine whether traditional serrated adenoma (TSA) results in an increased risk of developing subsequent serrated polyps or colorectal cancer (CRC).
林亮音;廖肇裕, Tsai, Jia-Huei;Cheng, Chien-Hsuan;Chen, Chien-Chuan;Lin, Yu-Lin;Lin, Liang-In;Chen, Mei-Ling;Liau, Jau-Yu   +1 more
core   +1 more source

Immunological effects of BRAF+MEK inhibition

OncoImmunology, 2018
Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted therapies based on BRAF and MEK inhibition also seem to have a long-term beneficial effect, which is ...
Paolo A. Ascierto, Reinhard Dummer
doaj   +1 more source

DETECTION OF SOMATIC MUTATIONS IN THE BRAF GENE BY PYROSEQUENCING

Сибирский онкологический журнал, 2021
Introduction. Detection of somatic mutations in the BRAF gene can be used in clinical oncology to clarify the diagnosis, select therapy and assess the prognosis of the disease.
O. P. Dribnokhodova, E. A. Dunaeva, G. V. Leshkina, E. A. Yarygina, A. Yu. Bukharina, Ya. A. Voiciehovskaya, E. V. Borisova, S. K. Bormotova, A. I. Daoud, V. N. Khlavich, K. O. Mironov   +10 more
doaj   +1 more source

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models [PDF]

, 2018
Background: Mounting evidence suggests that RAF-mediated MEK activation plays a crucial role in paradox MAPK (re)activation, leading to resistance and therapeutic failure with agents hitting a single step along the MAPK cascade.
Francesco Cognetti, Del Curatolo, Anais, Falcone, Italia, Fabiana Conciatori, Sette,Giovann i, Milella, Michele, Marabese, Mirko, Ciuffreda, Ludovica, Sabrina D’Agosto, De Maria Marchiano, Ruggero, Conciatori, Fabiana, De Maria, Ruggero, Scarpa, Aldo, Massimo Broggini, Sette, Giovanni, Del Bufalo, Donatella, Giovanni Sette, Senji Shirasawa, Teresa De Luca, D’Agosto, Sabrina, Shirasawa, Senji, Isabella Sperduti, Chiara Bazzichetto, Anais Del Curatolo, Aldo Scarpa, Ruggero De Maria, Ludovica Ciuffreda, D'Agosto, Sabrina, Donatella Del Bufalo, Broggini, Massimo, Cognetti, Francesco, Vincenzo Corbo, Sperduti, Isabella, Ursula Cesta Incani, Mirko Marabese, Eramo, Adriana, De Luca, Teresa, Italia Falcone, Bazzichetto, Chiara, Cesta Incani, Ursula, Adriana Eramo, Corbo, Vincenzo, Michele Milella   +42 more
core   +1 more source

Synthesis of potential inhibitors of BRAF V600E [PDF]

, 2023
reservedSintesi di potenziali inibitori di BRAF V600E derivanti da un pregresso studio di docking. Sono stati sintetizzati diversi analoghi da testare successivamente in vitro per confermarne l'attività inibitoria.
CALZAVARA, ANDREA
core  

Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma [PDF]

, 2022
Background. The treatment and prognosis of metastatic melanoma have changed during the last decade to include immunotherapy or targeted therapy as standard therapeutic options for BRAF-mutated melanoma.
Ondrej Kubecek, Peter Priester, Jindrich Kopecky, Hana Vosmikova, Eva Cermakova, Aneta Kyllarova   +5 more
core   +1 more source

Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia

Epigenetics, 2018
Colorectal cancer is a major cause of cancer death and approximately 20% arises within serrated polyps, which are under-recognized and poorly understood.
Catherine E. Bond, Cheng Liu, Futoshi Kawamata, Diane M. McKeone, Winnie Fernando, Saara Jamieson, Sally-Ann Pearson, Alexandra Kane, Susan L. Woods, Tamsin R. M. Lannagan, Roshini Somashekar, Young Lee, Troy Dumenil, Gunter Hartel, Kevin J. Spring, Jennifer Borowsky, Lochlan Fennell, Mark Bettington, Jason Lee, Daniel L. Worthley, Barbara A. Leggett, Vicki L. J. Whitehall   +21 more
doaj   +1 more source

Agents to treat BRAF-mutant lung cancer [PDF]

, 2019
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be
Jean G Bustamante Alvarez, Gregory A Otterson   +1 more
core   +1 more source